Early Single Instillation Chemotherapy Is Very Beneficial and Should Be the Standard Approach in Non-Muscle-Invasive Bladder Cancer

European Urology, Supplements

Volumn 8, Issue 5, 2009, Pages 464-469

  Solsona, Eduardo ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Early single instillation chemotherapy; Non muscle invasive bladder; Recurrence rate

Indexed keywords

BCG VACCINE; EPIRUBICIN; MITOMYCIN C; PLACEBO; THIOTEPA; TUMOR MARKER;

ANXIETY; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CARCINOMA IN SITU; CHEMICAL CYSTITIS; CLINICAL TRIAL; COST CONTROL; DRUG EFFICACY; DRUG INSTILLATION; DRUG SAFETY; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SINGLE DRUG DOSE; SKIN ALLERGY; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 60049094843     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.01.001     Document Type: Review

References (27)

1. Herr H.W., Laudone V.P., and Whitmore W.F. An overview of intravesical therapy for superficial bladder tumors. J Urol 138 (1987) 1363-1368
2. Lamm D.L. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19 (1992) 573-580
3. Pawinski A., Sylvester R., Kurth K.H., et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 156 (1996) 1934-1940
4. Ali-El-Dein B., Nave A., El-Baz M., Asma S., and Ashamallah S. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transuretral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 79 (1997) 731-735
5. Okamura K., Ono Y., Kinukawa T., et al. Randomized study of single early instillation of (2″R)-4′-0- tetrahydropyrannyl-doxorubicin for a single superficial blander carcinoma. Cancer 94 (2002) 2363-2368
6. Rajala P., Kaasinen E., Raitanen M., Liukkonen T., Rintala E., and Finnbladder Group. Perioperative sinble dose instillation of epirubicin or interferon-∝ after transuretral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study-Finnbladder III long-term results. J Urol 168 (2002) 981-985
7. Oosterlinck W., Kurth K.H., Schröder F., Bultinck J., Hammond B., and Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149 (1993) 749-752
8. Tolley D.A., Hargreave T.B., Smith P.H., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow-up. J Urol 155 (1996) 1233-1238
9. Solsona E., Iborra I., Ricós J.V., Monrós J.L., Casanova J., and Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 161 (1999) 1120-1123
10. Berrum-Svennung I., Granfors T., Jahnson S., Boman H., and Holmäng S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 179 (2008) 101-106
11. Sylvester R.J., Oosterlinck W., and van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomised clinical trials. J Urol 171 (2004) 2186-2190
12. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
13. Hall M.C., Chang S.S., Dalbagni G., et al. Guidelines for the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis): 2007 update. J Urol 178 (2007) 2314-2330
14. Richards B., Blandy J., Bloom H.G.J., et al. The effect of intravesical Thio-tepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a MRC randomized trial: MRC Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer. Br J Urol 73 (1994) 632-638
15. Zincke H., Utz D.C., Taylor W.F., Myers R.P., and Leary F.J. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumour recurrence: a prospective, randomized, double-blind, controlled trial. J Urol 129 (1983) 505-509
16. Hedelin H., Holmäng S., and Wiman L. The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol 36 (2002) 344-347
17. Oddens J.R., van der Meijden A.P.M., and Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?. Eur Urol 46 (2004) 336-338
18. Soloway M.S., and Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 46 (1980) 1158-1163
19. Soloway M.S., and Martino C. Prophylaxis of bladder tumor implantation: intravesical and systemic chemotherapy. Urology 7 (1976) 29-34
20. Whelan P., Griffiths G., Stower M., et al. Preliminary results of a MRC randomised controlled trial of post-operative irrigation of superficial bladder cancer. Proc Am Soc Clin Oncol 20 (2001) 1223 abstract 708
21. Masters J.R., Popert R.J., Thompson P.M., Gibson D., Coptcoat M.J., and Parmar M.K. Intravesical chemotherapy with epirubicin: a dose response study. J Urol 161 (1999) 1490-1493
22. Bouffioux C., Kurth K.H., Bono A., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol 153 (1995) 934-941
23. Iborra I., Ricós J.V., Monrós J.L., Dumont R., Casanova J., and Solsona E. Resultados de un estudio de quimioprofilaxis intravesical, prospectivo, doble aleatorio, entre dos drogas: La Adriamicina y el mitomicin; y dos modos de iniciar las instilaciones: precoz y tardío. Efecto sobre la recidiva y la progresión. Arch Esp Urol 45 (1992) 1001-1007
24. Hendricksen K., Witjes W.P.J., Idema J.G., et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 53 (2008) 984-991
25. Pan J.S., Slocum H.K., Rustum Y.M., Greco W.R., Gaeta J.F., and Huben R.P. Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. J Urol 142 (1989) 1589-1593
26. Kaasinen E., Rintala E., Hellström P., et al., FinnBladder Group. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42 (2002) 167-174
27. Rajala P., Liukkonen T., Raitanen M., et al. Transurethral resection with perioperative instillation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study-Finnbladder III. J Urol 161 (1999) 1133-1135